Mark Conley - Jun 4, 2024 Form 3 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role: Interim Chief Financial Officer, Vice President of Finance
Signature: Mark Conley
Stock symbol: SABS
Transactions as of: Jun 4, 2024
Transactions value $: $0
Form type: 3
Date filed: 6/24/2024, 05:00 PM
Previous filing: Mar 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SABS	Employee Stock Option (right to buy)							Jun 4, 2024	Common Stock	25K	$4.79	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter. The options were granted on November 6, 2023.
F2	Represents options to purchase shares of common stock pursuant to the Registrant's 2021 Omnibus Equity Incentive Plan.
F3	Reflects the 1-for-10 reverse stock split of the Registrant's common stock, which became effective January 5, 2024.

Remarks:

Interim Chief Financial Officer, Vice President of Finance